Literature DB >> 1086476

Cells that express viral antigens but lack H-2 determinants are not lysed by immune thymus-derived lymphocytes but are lysed by other antiviral immune attack mechanisms.

R M Zinkernagel, M B Oldstone.   

Abstract

Murine F9 teratoma cells do not express major transplantation antigens detectable by either serologic or alloreactive assays of thymus-dependent lymphocytes (T cells). Such cells can be infected with lymphocytic choriomeningitis virus or vaccinia virus, do express viral antigens on the cell surface, and can release infectious virus in amounts equivalent to those of other H-2 bearing murine cell lines. Immunologic injury of virus-infected F9 cells occurs after the addition of specific antiviral antibody and complement or of specific antiviral antibody and unsensitized lymphoid cells (antibody-mediated cell-dependent killing). In contrast, injury does not follow the addition of immune cytotoxic T cells. These results indicate that possession of H-2 antigens is not a requirement for a cell's infection by or production of virus. Further, expression of viral antigens on the cell's surface, although adequate for antibody-mediated immune injury, is by itself insufficient for direct T cell-mediated lysis. The major transplantation antigens thus probably represent the cell surface structures that are crucial for T-mediated cell wall damage that results in chromium release.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1086476      PMCID: PMC431179          DOI: 10.1073/pnas.73.10.3666

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Virus-specific T-cell-mediated cytotoxicity across the H-2 barrier to virus-altered alloantigen.

Authors:  R M Zinkernagel
Journal:  Nature       Date:  1976-05-13       Impact factor: 49.962

2.  A plaque neutralization method for arboviruses.

Authors:  E Earley; P H Peralta; K M Johnson
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

3.  Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells.

Authors:  P Perlmann; H Perlmann; H Wigzell
Journal:  Transplant Rev       Date:  1972

4.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

5.  Human lymphocytes recognise mouse alloantigens.

Authors:  K F Lindahl; F H Bach
Journal:  Nature       Date:  1975-04-17       Impact factor: 49.962

6.  Absence of H-2 antigens capable of reacting with cytotoxic T cells on a teratoma line expressing a T/t locus antigen.

Authors:  J Forman; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

7.  Identification of the cell population involved in viral-specific cell-mediated cytotoxicity in man: evidence for T cell specificity.

Authors:  M Rola-Pleszczynski; R C Hurtado; J N Woody; K W Sell; M M Vincent; S A Hensen; J A Bellanti
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

8.  Structural similarities between a product of the T/t-locus isolated from sperm and teratoma cells, and H-2 antigens isolated from splenocytes.

Authors:  E S Vitetta; K Artzt; D Bennett; E A Boyse; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

9.  H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;.

Authors:  R M Zinkernagel; P C Doherty
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

View more
  21 in total

Review 1.  Rheumatoid arthritis--a virus disease?

Authors:  A M Denman
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

Review 2.  HIV antibodies for treatment of HIV infection.

Authors:  David M Margolis; Richard A Koup; Guido Ferrari
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 3.  Tumor viruses and early mouse embryos.

Authors:  F Kelly; H Condamine
Journal:  Biochim Biophys Acta       Date:  1982-04-29

4.  Immune response in rabbits to surface components of extracellular and intracellular forms of vaccinia virus.

Authors:  N Balachandran; P Seth; L N Mohapatra
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

5.  Minor histocompatibility antigen expression on F9 embryonal carcinoma cells revealed by T-cell mediated responses.

Authors:  M C Simmler; P Avner; J P Levy
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

6.  Does the major histocompatibility complex serve as a specific receptor for Semliki Forest virus?

Authors:  M B Oldstone; A Tishon; F J Dutko; S I Kennedy; J J Holland; P W Lampert
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

7.  Variation of expression of histocompatibility antigens on tumor cells: absence of H-2Kk-gene products from a gross-virus-induced leukemia in BALB.K.

Authors:  W Schmidt; L Leben; G Atfield; H Festenstein
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

8.  Analysis of the xenogeneic T-cell response to murine H-2 negative embryonal carcinoma cells.

Authors:  R Aspinall; P L Stern
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

9.  Enrichment of rat NK cytotoxicity for H2-negative murine embryonal carcinoma cells by panning and short-term culture in TCGF.

Authors:  S M Bell; R Aspinall; P L Stern
Journal:  Immunology       Date:  1984-09       Impact factor: 7.397

10.  Natural and immune cytolysis of canine distemper virus-infected target cells.

Authors:  W R Shek; R D Schultz; M J Appel
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.